Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | AMY2A | P04746 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892843 | 0.94 | AMY2A (0.39) | AMY1ALGALS8OGAAMY2APYGB | |
| SCHEMBL9912325 | 0.94 | AMY2A (0.39) | AMY1ALGALS8OGAAMY2APYGB | |
| SCHEMBL14025434 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL21077738 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL15081843 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL23603150 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL21083400 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL22423226 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL13471590 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 | |
| SCHEMBL9914030 | 0.90 | LGALS8 (0.45) | AMY1ALGALS8OGAPYGBSLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772192-B2 | Compositions and methods for treatment of disease with acetylated disaccharides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161598-A1 | Compositions and methods for treatment of disease with acetylated disaccharides | ASAH2, ALG1, MAN2B1 | AMY1A 230/4885LGALS8 456/4885OGA 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.